U.S. markets have been on a historic bull run since the end of the pandemic. However, many investors may start to be wary.

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Cassava Sciences (SAVA) stock in focus as company posts better than expected Q3 earnings and reaffirms Phase 3 timeline for ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Short SAVA slightly under 32.68, target 24.58, stop loss @ 32.77 Check the time stamp on this data. Updated AI-Generated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.